Advertisement

Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics

  • Priyankar PalEmail author
  • Prabhas Prasun Giri
  • Rajiv Sinha
Original Article
  • 59 Downloads

Abstract

Objectives

To assess the efficacy of cyclosporine (CsA) in patients of oral steroid unresponsive or steroid dependent systemic juvenile idiopathic arthritis (sJIA); to evaluate the optimum dosage and blood level of CsA to achieve and maintain remission and to observe for side-effects on prolonged usage.

Methods

This prospective observational study was conducted on children with steroid dependent /refractory sJIA admitted at the Institute of Child Health, Kolkata from July 2009 through November 2014. A total of 82 sJIA was diagnosed; 15 were steroid dependent /refractory and were included as candidates for cyclosporine therapy.

Results

CsA was used in 15 patients; 13 showed a favourable response with significant steroid sparing effect and minimal toxicity.

Conclusion

CsA was found to be effective in almost 75% of frequently relapsing steroid dependent sJIA to achieve and maintain remission. The average cost of therapy for a 20 kg patient on CsA was found to be 10,000 INR (132 EURO)/ patient over a 6 mo period; which would amount to 100,000 INR (1318 EURO)/patient with Tocilizumab for the same duration.

Keywords

Systemic arthritis Cyclosporine Systemic juvenile idiopathic arthritis treatment 

Notes

Authors’ Contribution

PP conceptualised the project. Both PP and PPG were involved in patient management and data collection. All three authors drafted the manuscript. Prof. Apurba Ghosh, Director, Institute of Child Health, Kolkata will act as guarantor for this paper.

Compliance with Ethical Standards

Conflict of Interest

None

References

  1. 1.
    Beukelmen T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–82.CrossRefGoogle Scholar
  2. 2.
    Pay S, Turkcapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.CrossRefGoogle Scholar
  3. 3.
    Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505–15.CrossRefGoogle Scholar
  4. 4.
    Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071–5.Google Scholar
  5. 5.
    De Benedetti F, Brunner HI, Ruperto N, et al; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.Google Scholar
  6. 6.
    Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis: results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24:599–605.Google Scholar
  7. 7.
    Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis: results of a 10-year prospective study. Rheumatology (Oxford). 2001;40:907–13.CrossRefGoogle Scholar
  8. 8.
    Ostensen M, Hoyerall HM, Kass E. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol. 1988;15:1536–8.Google Scholar
  9. 9.
    Wells G, Haguernauer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell P. Cyclosporine for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2:CD001083.Google Scholar
  10. 10.
    Gremese E, Ferraccioli GF. Benefit/risk of cyclosporine in rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:S101–7.Google Scholar
  11. 11.
    Ostensen M, Hoyeraal HM, Kass E. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol. 1988;15:1536–8.Google Scholar
  12. 12.
    Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol. 1993;11:203–8.Google Scholar
  13. 13.
    Ravelli A, Moretti C, Tomporini F, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:69–72.Google Scholar
  14. 14.
    Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333:137–41.Google Scholar
  15. 15.
    Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24:2436–43.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2019

Authors and Affiliations

  • Priyankar Pal
    • 1
    Email author
  • Prabhas Prasun Giri
    • 2
  • Rajiv Sinha
    • 3
  1. 1.Department of Pediatrics, Pediatric Rheumatology UnitInstitute of Child HealthKolkataIndia
  2. 2.Department of PediatricsInstitute of Child HealthKolkataIndia
  3. 3.Pediatric Nephrology Unit, Department of PediatricsInstitute of Child HealthKolkataIndia

Personalised recommendations